Dr Richard Gilson

Photo

Personal Profile

Name: Richard Gilson Email: r.gilson@ucl.ac.uk
Title: Dr Tel: +44 (0)20 3108 2103
Department: Infection & Population Health Fax: +44 (0)20 3108 2079
Position: Reader in Sexual Health and HIV Address: Research Department of Infection and Population Health, The Mortimer Market Centre, London, WC1E 6JB
Research Domain: Infection, Immunology & Inflammation, Personalised Medicine, Populations & Lifelong Health Web Page:  

Profile

Research Description

The objective of the Centre for Sexual Health and HIV Research is to improve the sexual health of the population by improving the management of patients with HIV infection and other sexually transmitted infections, and by devolpoing effective prevention strategies. Within the Centre, the clinical research group focusses on observational studies, prevention and treatment trials related to HIV infection and its complications and co-infections, hepatitis virus infections and human papilloma viirus (HPV) infection. We collaborate closely with the large clinical service run by Camden Provider Services (Central and North West London NHS Foundation Trust), recruiting patients at the Mortimer Market Centre and Archway Centre to randomised clinical trials and other studies. We work closely with the MRC Clinical Trials Unit and the UCL CTU to design and undertake studies. The work is funded from multiple sources including the MRC, Wellcome Trust, NIHR and the pharmaceutical industry.

My particular interests include co-infection with HIV and viral hepatitis (prevalence, transmission, natural history, immunology and response to treatment), and the use of HIV cohort studies (UK CHIC, the MRC Seroconverters Register and the UCL Partners HIV Cohort) to examine treatment outcomes and complications. HPV work includes treatment trials, and the use of HPV vaccines to prevent disease in groups at high risk of acquisition and disease incidence including MSM.

Research Activities

HIV cohort studies

HPV infection

Hepatitis-HIV co-infection

Hepatology

Immunopathogenesis of hepatitis B virus infection

clinical trials in STIs

Education Description

Teaching on the undergraduate curriculum for medical students in HIV and sexual health, UCL MSc in Sexually Transmitted Infections and HIV, and various other masters and diploma courses.

UCL Collaborators

Prof William Rosenberg; Prof Mala Maini; Dr Michael Jacobs; Prof Geoffrey Dusheiko; Prof Arne Akbar; Dr Teresa Hill; Prof Mary Collins; Prof Dame Anne Johnson; Prof Deenan Pillay; Prof Caroline Sabin

External Collaborators

Publications

    2014

    • McDonnell J, Haddow L, Daskalopoulo M, Lampe F, Speakman A, Gilson R, Phillips A, Sherr L, Wayal S, Harrison J, Antinori A, Maruf P, Schembri A, Johnson M, Collins S, Rodger A (2014). Minimal cognitive impairment in HIV positive men who have sex with men (MSM) in the United Kingdom: comparison with the general population and HIV negative MSM.. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 67(2), 120 - 127.
    • May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C, for the UK Collaborative HIV Cohort (UK CHIC) Study (2014). Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study.. AIDS, , - . doi:10.1097/QAD.0000000000000243
    • Dolling D, Desai M, Saunders J, Mackie N, McOwan A, Youssef E, Bowman C, Lacey C, Schembri G, Gilson R, Sullivan A, Reeves I, Bayley J, Fox J, Taylor S, Khoo S, Gafos M, Nardone A, Gill N, Dunn D, McCormack S, Study PROUD (2014). Who accesses PrEP? An analysis of baseline data in the PROUD pilot. HIV MEDICINE, 15, 15 - 15.
    • Kall M, Shahmanesh M, Nardone A, Gilson R, Delpech V (2014). Development of Positive Voices: the national survey of people living with HIV. HIV MEDICINE, 15, 88 - 88.
    • Inshaw J, Leen C, Fisher M, Gilson R, Hawkins D, Fox J, Mclean K, Fidler S, Phillips A, Babiker A, Porter K (2014). The effect of HCV infection duration on HIV disease progression.
    • Parsons V, Phillips A, Gilson R, Fidler S, Fox J, Fisher M, Johnson A, Hawkins D, McLean K, Johnson M, Collins S, Hart G, Porter K (2014). Temporal trends in cART initiation amongst HIV seroconverters in the UK. HIV MEDICINE, 15, 3 - 3.
    • Desai M, Burns F, Mercey D, Nardone A, Muniina P, Sharp T, Wayal S, Gilson R (2014). Active recall of men who have sex with men (MSM) for an HIV/STI testing: a feasible and effective strategy?.
    • Desai M, Woodhall S, Burns F, Mercey D, Nardone A, Gilson R (2014). Active recall for HIV/STI testing: a systematic review.
    • Thornton A, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Gilson R, Jose S, Main J, Rodger A, Sabin C, Taylor C, Nelson M (2014). Hepatitis B infection among individuals attending for care in the UK Collaborative HIV Cohort (CHIC) Study. HIV MEDICINE, 15, 137 - 137.
    • Brima N, Lampe F, Smith C, Phillips A, Copas A, Gilson R, Johnson M, Williams I, Milinkovic A, Burns F, Kinloch-de Loes S, Edwards S (2014). Early virological response to antiretroviral therapy: can we predict earlier who is unlikely to achieve a response at 6 months?. HIV MEDICINE, 15, 129 - 129.
    • Thornton A, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Gilson R, Jose S, Main J, Nelson M, Rodger A, Taylor C, Sabin C (2014). Viral hepatitis testing patterns among HIV-positive individuals in the UK Collaborative HIV Cohort (UKCHIC) study. HIV MEDICINE, 15, 91 - 92.
    • Jose S, Quinn K, Hill T, Leen C, Walsh J, Hay P, Fisher M, Post F, Nelson M, Gompels M, Johnson M, Chadwick D, Gilson R, Sabin C, Fidler S (2014). Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy.. AIDS, , - . doi:10.1097/QAD.0000000000000242
    • Jose S, Hamzah L, Campbell L, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P, Johnson M, Chadwick D, Nitsch D, Jones R, Sabin C, Post F, on behalf of the UK Collaborative HIV Cohort Study Steering Committee (2014). Incomplete reversibility of eGFR following tenofovir exposure.. J Infect Dis, , - . doi:10.1093/infdis/jiu107
    • Miltz A, Price H, Shahmanesh M, Copas A, Gilson R (2014). Systematic Review and Meta-Analysis of L1-VLP-Based Human Papillomavirus Vaccine Efficacy against Anogenital Pre-Cancer in Women with Evidence of Prior HPV Exposure.. PLoS One, 9(3), e90348 - . doi:10.1371/journal.pone.0090348
    • Rodger AJ, Phillips A, Speakman A, Gilson R, Fisher M, Wilkins E, Anderson J, Johnson M, O'Connell R, Collins S, Elford J, Sherr L, Lampe FC, ASTRA (Antiretrovirals, Sexual Transmission Risk and Attitudes) Study Group (2014). Attitudes of People in the UK with HIV Who Are Antiretroviral (ART) Naïve to Starting ART at High CD4 Counts for Potential Health Benefit or to Prevent HIV Transmission.. PLoS One, 9(5), e97340 - . doi:10.1371/journal.pone.0097340

    2013

    • Pallett LJ, Haniffa M, Jover-Cobos M, Schurich A, Das A, Gill U, Davies N, Ghosh I, Gilson R, Kennedy PT, Bertoletti A, Maini MK (2013). Expansion of arginase-expressing myeloid-derived suppressor cells in hepatotropic viral infections.
    • Rodger AJ, Lodwick R, Schecter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A (2013). Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT Trials compared to the general population. AIDS, 27, 973 - 979.
    • Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C, Gompels M, Gilson R, Post F, Hay P, Sabin C, UK Collaborative HIV Cohort Study (UK CHIC) (2013). The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations.. HIV Med, , - . doi:10.1111/hiv.12103
    • Whitlock G, Herbert S, Copas A, Gilson R, Ainsworth J (2013). Avascular necrosis in HIV-infected patients: a case-control study.. Int J STD AIDS, 24(10), 799 - 803. doi:10.1177/0956462413482814
    • Price H, Gilson R, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L (2013). Suppression of HBV by tenofovir in HBV/HIV coinfected patients: A systematic review and meta-analysis. PLoS ONE, 8(7), - . doi:10.1371/journal.pone.0068152
    • Price H, Gilson R, Mercey D, Copas A, Parry J, Nardone A, Hart G (2013). Hepatitis C in men who have sex with men in London - a community survey. HIV Medicine, 14(9), 578 - 580. doi:10.1111/hiv.12050
    • Whitlock GG, Warwick Z, Perry N, Ottewill M, Richardson D, Fisher M, Gilson R (2013). Why do men who have sex with men and who are at high risk of HIV infection, decline HIV testing?. Int J STD AIDS, 24(6), 503 - . doi:10.1177/0956462412473886
    • Haddow LJ, Floyd S, Copas AJ, Gilson RJC (2013). A systematic review of the screening accuracy of the HIV dementia scale and international HIV dementia scale. PLoS One, 8(4), - . doi:10.1371/journal.pone.0061826
    • Rodger A, Phillips A, Sturgeon K, Sewell J, Asboe D, Fedele S, Nwokolo N, Gilson R, De Esteban N, Jennings L, Gompels M, Allan S, Clay S, Engler B, Wandolo E, Campbell L, Hobbs K, Fisher M, Perry N, Dhar J, Mashonganyika L, O'Connell R, Tawana C, Bruun T, Cambiano V, Collins S, Nightingale A, Lundgren J (2013). Continued high levels of condomless sex in serodifferent couples when the positive partner is on antiretroviral therapy: the PARTNER study.
    • Lampe F, Speakman A, Sherr L, Phillips A, Collins S, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, Daskalopoulou M, Edwards S, McDonnell J, Perry N, Jones M, O'Connell R, Lascar M, Hart G, Johnson A, Miners A, Geretti A, Burman W, Elford J, Rodger A (2013). Psychological and physical symptoms and sexual behaviour among HIV-diagnosed men who have sex with men (MSM) in the UK.
    • Haddow LJ, Accoroni A, Cartledge JD, Manji H, Benn P, Gilson RJ (2013). Routine detection and management of neurocognitive impairment in HIV-positive patients in a UK centre.. Int J STD AIDS, 24(3), 217 - 219. doi:10.1177/0956462412472452
    • Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C, UK Collaborative HIV Cohort Study (2013). Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.. J Antimicrob Chemother, 68(6), 1354 - 1359. doi:10.1093/jac/dkt029
    • Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F, Johnson AM, Walker-Nthenda L, Dunn D, Porter K, on behalf of the UK Register of HIV Seroconverters (2013). Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.. PLoS One, 8(9), e75608 - . doi:10.1371/journal.pone.0075608
    • Speakman A, Rodger A, Phillips AN, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, O'Connell R, Lascar M, Aderogba K, Edwards S, McDonnell J, Perry N, Sherr L, Collins S, Hart G, Johnson AM, Miners A, Elford J, Geretti AM, Burman WJ, Lampe FC (2013). The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) Study. Design, Methods and Participant Characteristics.. PLoS One, 8(10), e77230 - . doi:10.1371/journal.pone.0077230
    • O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R, Mackie N, Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman A, Post F, Johnson M, Sabin CA, Phillips AN (2013). Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.. AIDS, , - . doi:10.1097/QAD.0000000000000165

    2012

    • Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, Edwards S, McDonnell J, Perry N, Aderogba K, Hart G, Johnson A, Collins S, Elford J, Miners A, Geretti A, Burman B, Rodger A (2012). ART use, viral suppression, and sexual behaviour among HIV-diagnosed MSM in the UK: results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study. doi:10.7448/IAS.15.6.18143
    • Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, Edwards S, McDonnell J, Perry N, Aderogba K, Hart G, Johnson A, Collins S, Elford J, Miners A, Geretti A, Burman B, Rodger A (2012). ART use, viral suppression, and sexual behaviour among HIV-diagnosed MSM in the UK: results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study..
    • Sultan BJ, Fish R, Carrick G, Gilson R, Robinson A, Mercey D, White J, Benn P (2012). IS POOLING OF SELF-TAKEN SPECIMENS AN EFFECTIVE AND ACCEPTABLE METHOD OF TESTING FOR SEXUALLY TRANSMITTED INFECTIONS IN MSMS?. doi:10.1136/sextrans-2012-050601c.98
    • Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Anderson J, Wilkins E, Broussard C, McDonnell J, Perry N, Scourse R, George V, Hart G, Johnson A, Collins S, Miners A, Elford J, Geretti A-M, Burman W, Rodger A (2012). Depression and virological status among UK HIV outpatients: results from a multicentre study.
    • Milinkovic A, Pavlou M, Furco A, Copas A, Arenas-Pinto A, Connolly JO, Edwards S, Gilson R, Williams I (2012). Factors associated with increased risk of tenofovir-related renal toxicity: case-control study.
    • Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA, UK Collaborative HIV Cohort (CHIC) Study (2012). Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.. HIV Med, 13(1), 73 - 78. doi:10.1111/j.1468-1293.2011.00956.x
    • Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T, Johnson M, Gilson R, Bansi L, Easterbrook P, Fisher M, Walsh J, Orkin C, Ainsworth J, Leen C, Sabin C, UK Collaborative HIV Cohort (UK CHIC) Study (2012). Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?. J Infect Dis, 205(4), 540 - 547. doi:10.1093/infdis/jir380
    • Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees (2012). Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.. J Antimicrob Chemother, 67(4), 995 - 1000. doi:10.1093/jac/dkr569
    • Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M, Pillay D, Rodger A, Taylor C, Gilson R, UK Collaborative HIV Cohort Hepatitis Group, Steering Committee (2012). Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study.. PLoS One, 7(11), e49314 - . doi:10.1371/journal.pone.0049314
    • Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G, Gilson R, ChinAleong J, Kennedy P, Maini MK (2012). Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection.. PLoS One, 7(10), e47648 - . doi:10.1371/journal.pone.0047648
    • Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M, Sabin C, UK Collaborative HIV Cohort Study (2012). Biomarkers to monitor safety in people on art and risk of mortality.. J Acquir Immune Defic Syndr, 60(1), 51 - 58. doi:10.1097/QAI.0b013e31824d2134

    2011

    • Nebbia G, Peppa D, Schurich A, Khanna P, Singh H, Rosenberg W, Dusheiko G, Gilson R, Chinaleong J, Kennedy P, Maini M (2011). Role of the TIM-3/Galectin-9 pathway in chronic hepatitis B infection.
    • Albert M, Benito J, Bhagani S, Boesecke C, Deterding K, Dominguez S, Fisher M, Fontanet A, Garcia D, Gilson R, Guiguet M, Hoepelman AIM, Horban A, Katlama C, Mallolas J, Page E, Peters L, Pozniak A, Prins M, Puoti M, Rauch A, Rodger A, Rockstroh JK, Soriano V, Stephan C, Thibault V, Tural C, Valantin MA, van de Laar T, van der Meer J, Vella S, Vogel M, de Wit S, Autran B, Clotet B, Danta M, Journiac M, Matthews G, Meyer-Olson D, Nelson M, Schmidt R, Wedemeyer H, European AIDS Treatment Network (NEAT) (2011). Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. AIDS, 25(4), 399 - 409. doi:10.1097/QAD.0b013e328343443b
    • Nathan M, Sheaff M, Fox P, Goon P, Gilson R, Lacey C (2011). Anal Neoplasia and Cancer: Early treatment of anal intraepithelial neoplasia. BMJ: British Medical Journal, 343, - . doi:10.1136/bmj.d7717
    • Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C, for the UK CHIC Steering Committee (2011). Authors' response to Drs Scourfield, Jackson and Nelson.. HIV Med, 12(7), 450 - 451. doi:10.1111/j.1468-1293.2011.00932.x
    • Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, Ross JD, Lacey CJ, QOLIGEN study group (2011). The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK.. Sex Transm Infect, 87(6), 458 - 463. doi:10.1136/sextrans-2011-050073
    • Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J, Anderson J, Gompels M, Dunn D, Johnson MA, Phillips AN, Pillay D, Leen C, Easterbrook P, Gazzard B, Fisher M, Sabin CA (2011). Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.. HIV Med, 12(10), 583 - 593. doi:10.1111/j.1468-1293.2011.00929.x
    • Whitlock GG, Lowndes CM, Mercey DE, Gilson R (2011). Do HIV-infected individuals test for sexually transmitted infections at another sexual health clinic?. Sex Transm Infect, 87(3), 253 - . doi:10.1136/sti.2010.049072
    • Sethi G, Edwards S, Gilson R, Sabin C (2011). Treatment outcomes in Black and Minority Ethnic (BME) and White men who have sex with men (MSM).
    • Whitlock G, Warwick Z, Perry N, Ottewill M, Richardson D, Fisher M, Gilson R (2011). Why do men who have sex with men who are at high risk of HIV infection decline HIV testing?.
    • Peppa D, Micco L, Schurich A, Nebbia G, Khanna P, Singh H, Rosenberg W, Dusheiko G, Gilson R, Maini M (2011). Fratricide of HBV-specific CD8 T cells by NK cells mediated through the TRAIL pathway.
    • Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Phillips AN, Sabin CA, UK Collaborative HIV Cohort CHIC (2011). HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. EUR J NEUROL, 18(3), 527 - 534. doi:10.1111/j.1468-1331.2010.03291.x
    • Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA, for the UK Collaborative HIV Cohort (CHIC) study (2011). Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.. Neurology, 76(8), 693 - 700. doi:10.1212/WNL.0b013e31820d8b0b
    • Nathan M, Sheaff M, Fox P, Goon P, Gilson R, Lacey C (2011). Early treatment of anal intraepithelial neoplasia.. BMJ, 343, d7717 - .
    • May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C (2011). Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.. BMJ, 343, d6016 - .
    • Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA, UK CHIC Study Steering Committee (2011). Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.. Antivir Ther, 16(6), 805 - 814. doi:10.3851/IMP1818
    • Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C, UK CHIC Steering Committee (2011). Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.. HIV Med, 12(5), 289 - 298. doi:10.1111/j.1468-1293.2010.00881.x
    • Peppa D, Gill U, Micco L, Schurich A, Nebbia G, Singh H, Rosenberg W, Gilson R, Kennedy PT, Maini M (2011). Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients.

    2010

    • Richens J, Copas A, Sadiq ST, Kingori P, McCarthy O, Jones V, Hay P, Miles K, Gilson R, Imrie J, Pakianathan M (2010). A randomised controlled trial of computer-assisted interviewing in sexual health clinics.. Sex Transm Infect, 86(4), 310 - 314. doi:10.1136/sti.2010.043422
    • Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C (2010). The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. Journal of Viral Hepatitis, 17(8), 569 - 577.
    • Cozzi-Lepri A, Dunn D, Pillay D, Sabin CA, Fearnhill E, Geretti AM, Hill T, Kaye S, Bansi L, Smit E, Johnson M, Burns S, Gilson R, Cameron S, Easterbrook P, Zuckerman M, Gazzard B, Walsh J, Fisher M, Orkin C, Ainsworth J, Leen C, Gompels M, Anderson J, Phillips AN, Babiker A, Porter K, Sadiq T, Schwenk A, Mackie N, Winston A, Delpech V, UK Collaborative Group on HIV Drug Resistance , UK CHIC Study Group (2010). Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy. CLIN INFECT DIS, 50(9), 1275 - 1285. doi:10.1086/651684
    • Turner J, Aarons E, O'Farrell S, Price H, Ferns B, Copas A, Gilson R (2010). Hepatitis C viral load in semen of HIV-positive men during acute and chronic hepatitis C infection.
    • Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M, Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker A, Delpech V, UK Collaborative HIV Cohort Study Group (2010). Data linkage reduces loss to follow-up in an observational HIV cohort study.. J Clin Epidemiol, 63(10), 1101 - 1109. doi:10.1016/j.jclinepi.2009.12.007
    • Turner J, Bansi L, Gilson RJC, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C, on behalf of the UK Collaborative HIV Cohort (UK CHIC) study (2010). The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes.. Journal of Viral Hepatitis, 17, 569 - 577.
    • Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M, Porter K, Anderson J, Gompels M, Leen C, Ainsworth J, Orkin C, Nelson M, Rice B, Phillips A, UK Collaborative HIV Cohort (CHIC) Study and the Health Protection Agency (2010). Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.. HIV Med, 11(7), 432 - 438. doi:10.1111/j.1468-1293.2009.00809.x
    • Ray M, Logan R, Sterne JAC, Hernandez-Diaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Justice A, Gouler J, Lodi S, Phillips A, Seng R, Meyer L, Perez-Hoyos S, de Olalla PG, Herman MA, Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C, Orkin C, Anderson J, Pillay D, Delpech V, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, Sabin C, HIV-CAUSAL Collaboration (2010). The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS, 24(1), 123 - 137. doi:10.1097/QAD.0b013e3283324283
    • Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, Fisher M, Gilleece Y, Gilson R, Freedman A, Kulasegaram R, Agarwal K, Sabin C, Deacon-Adams C, BHIVA Viral Hepatitis Working Group (2010). British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010.. HIV Med, 11(1), 1 - 30. doi:10.1111/j.1468-1293.2009.00781.x
    • Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, UK CHIC Steering Committee (2010). Factors influencing lopinavir and atazanavir plasma concentration. Jounal of Antimicrobial Chemotherapy, 65(1), 129 - 137. doi:10.1093/jac/dkp408
    • Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T, Gilson R, Porter K, Easterbrook P, Delpech V, Bansi L, Leen C, Gompels M, Anderson J, Phillips AN, UK CHIC Steering Comm (2010). Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS, 24(5), 723 - 727. doi:10.1097/QAD.0b013e328333fa0f

    2009

    • Gilson R, Man S-L, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C, Pillay D, Schwenk A, Johnson M, Easterbrook P, Walsh J, Fisher M, Leen C, Anderson J, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study Group (2009). Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine, 11(2), 152 - 160. doi:10.1111/j.1468-1293.2009.00755.x
    • Gilson R, Ross J, Maw R, Rowen D, Sonnex C, Lacey CJN (2009). A multi-centre, randomised, double-blind, placebo-controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts.. Sexually Transmitted Infections, 85, 514 - 519. doi:10.1136/sti.2009.038075
    • Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA, United Kingdom Collaborative HIV C (2009). Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? United Kingdom Collaborative HIV Cohort Study Group. AIDS, 23(18), 2507 - 2515. doi:10.1097/QAD.0b013e3283320dfd
    • Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C, on behalf of the UK Collaborative HIV Cohort CHIC Study (2009). Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Journal of Acquired Immune Deficiency Syndromes, 52(3), 391 - 396. doi:10.1097/QAI.0b013e3181ab73cc
    • Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A (2009). Virological response to initial antiretroviral regimens containing abacavir or tenofovir. The Journal of Infectious Diseases, 200, 710 - 714.
    • Ewings F, Copas A, Fidler S, McLean K, Fisher M, Phillips A, Porter K, Hawkins D, Gilson R, Johnson M (2009). HIV-infected individuals co-infected with hepatitis C appear to have faster CD4 decline in the absence of ART but similar response once combination ART is initiated..
    • Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Webster G, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2009). Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology, 137(4), 1289 - 1300. doi:10.1053/j.gastro.2009.06.054
    • Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN, UK Collaborative HIV Cohort CHIC Study (2009). The associations between age, the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.. HIV Medicine, 10(1), 35 - 43. doi:10.1111/j.1468-1293.2008.00654.x
    • Peppa D, Dunn C, Pallant C, Das A, Khanna P, Dusheiko G, Gilson R, Maini MK (2009). The cytokine milieu impairs NK cell antiviral capacity in chronic HBV infection..
    • Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study (2009). CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK.. Haematologica, 94(6), 875 - 880. doi:10.3324/haematol.2008.002691

    2008

    • Pallant C, Christophides T, Khanna P, Dusheiko GM, Gilson RJ, Reynolds G, Adams DH, Maini MK, Dunn C (2008). CXCR6-directed recruitment of NK cells with pathogenic potential in HBV-related liver inflammation.
    • Bansi L, Turner J, Gilson R, Sabin C (2008). What constitutes an ALT flare and which factors are associated with such flares?.
    • Peppa D, Dunn C, Pallant C, Das A, Ellis G, Gilson R, Maini M (2008). Impaired innate immune responses in patients with chronic HBV infection.
    • Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, Peppa D, Gilson RJ, Gehring A, Bertoletti A, Maini MK (2008). Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. Journal of Clinical Investigation, 118(5), 1835 - 1845. doi:10.1172/JCI33402
    • Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, Schwenk A, Gilson R, Easterbrook P, Delpech V, Sabin CA, on behalf of the UK CHIC Study Group (2008). Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3. Journal of Acquired Immune Deficiency Syndromes, 47(2), 202 - 205. doi:10.1097/QAI.0b013e31815b1291
    • Dunn C, Brendish N, Jones M, Nebbia G, Brown D, Gilson RJ, Dusheiko GM, Jacobs M, Maini MK (2008). Impaired innate immune responses in patients with early acute HBV infection.
    • Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study (2008). Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. AIDS, 22(3), 349 - 356. doi:10.1097/QAD.0b013e3282f4709a
    • Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Nock D, Brettle R, Johnson M, Phillips A, Porter K, for the UK Register of HIV Seroconverters (2008). Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS, 22(1), 89 - 95. doi:10.1097/QAD.0b013e3282f3915e
    • Richens J, Copas A, Sadiq ST, Kingori P, McCarthy O, Jones V, Hay P, Miles K, Gilson R, Imrie J, Pakianathan M (2008). A three-arm randomised controlled trial comparing computer-assisted self-interview with computer-assisted physician interview and pen and paper face-to-face sexual history taking in a clinic setting..
    • Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, on behalf of the Liverpool TDM Database and the UKCHIC Study (2008). Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antiviral Therapy, 13(5), 675 - 685.
    • Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Frederick D, Neumann AU, Brosgart CL, Naoumov NV (2008). Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrobial Agents and Chemotherapy, 52(1), 312 - 320. doi:10.1128/AAC.00467-07
    • Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J, Gilson R, Fisher M, Bhagani S, Johnson M, Barton S (2008). Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak?. Sexually Transmitted Infections, 84(2), 111 - 116. doi:10.1136/sti.2007.027334
    • Turner J, Gikanga T, Jones V, Copas A, Cooper J, Stevens J, Aarons E, Gilson R (2008). Is there an unrecognised epidemic of hepatitis C infection in men who have sex with men?.
    • Cozzi-Lepri A, Dunn D, Pillay D, Sabin C, Fearnhill E, Phillips A, and the UKHIV Drug Resistance Database and UKCHIC Study Groups (2008). Long-term probability of detecting HIV drug resistance in drug-naïve patients starting currently recommended first-line combination ART..
    • Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA, on behalf of the UK Collaborative HIV Cohort CHIC Study Steering Committee (2008). Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Medicine, 9(1), 47 - 56.
    • Gompels M, Sabin C, Phillips A, Dunn D, and TUKCHIVCCHICS (2008). The frequency and clinical implications of a discordant CD4 count and CD4 percentage.
    • Lee KJ, Dunn D, Porter K, Gilson R, Bansi L, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C, for the United Kingdom Collaborative HIV Cohort CHIC Study (2008). Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS, 22(15), 1943 - 1950. doi:10.1097/QAD.0b013e32830e4cf3
    • Dunn C, Nebbia G, Jones M, Brendish N, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2008). Silencing of the early innate immune response in patients with acute hbv infection.

    2007

    • Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA, on behalf of the UK Collaborative HIV Cohort CHIC Study (2007). Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. The Lancet, 370(9603), 1923 - 1928. doi:10.1016/S0140-6736(07)61815-7
    • Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C, Orkin C, Anderson J, Pillay D, Delpech V, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, Sabin C (2007). HIV diagnosis at CD4 count above 500 Cells/mm(3) and progression to below 350 Cells/mm(3) without Antiretroviral therapy. JAIDS-J ACQ IMM DEF, 46(3), 275 - 278.
    • Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevie S, Johnson M, Gilson R, Tedder R, Geretti AM (2007). Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J MED VIROL, 79(10), 1464 - 1471. doi:10.1002/jmv.20954
    • Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, UK Collaborative HIV Cohort Study (2007). Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS, 21(13), 1717 - 1721. doi:10.1097/QAD.0b013e32827038bf
    • Ferns RB, Naoumov NV, Gilson RJ, Tedder RS (2007). Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.. Journal of Clinical Virology, 39(3), 199 - 204. doi:10.1016/j.jcv.2007.04.008
    • UK Collaborative Group on HIV Drug Resistance , UK CHIC Steering Committee , UK Register of HIV Seroconverters Steering Committee (2007). Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS, 21(8), 1035 - 1039.
    • Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson M, Delpech V, Phillips A, Sabin C, UK CHIC Study (2007). CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Medicine, 8(3), 135 - 141. doi:10.1111/j.1468-1293.2007.00443.x
    • Turner J, Gilson R (2007). Acute hepatitis C: presentation and outcome of early treatment..
    • Nebbia G, Sabin CA, Dunn DT, Geretti AM, on behalf of the UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort (CHIC) Study Group (2007). Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. Journal of Antimicrobial Chemotherapy, 59(5), 1013 - 1016. doi:10.1093/jac/dkm067
    • Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Dunn D, Delpech V, Taylor GP, Walsh JC, Phillips AN, United Kingdom Collaborative HIV Cohort (CHIC) Study Group (2007). Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.. AIDS, 21(11), 1423 - 1430. doi:10.1097/QAD.0b013e3281532ca7
    • Hughes R, Sabin C, Sterne JAC, for the UKCHIC Study Group (2007). Long-term trends in CD4 count in patients starting HAART: UK-CHIC study.
    • Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti A-M (2007). Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.. Journal of Medical Virology, 79(10), 1464 - 1471. doi:10.1002/jmv.20954

    2006

    • Gilson R, Brook MG (2006). Hepatitis A, B, and C.. Sex Transm Infect, 82 Suppl 4, iv35 - iv39. doi:10.1136/sti.2006.023218
    • Das A, Kennedy P, Lopes AR, Dunn C, Gilson RJ, Bertoletti A, Maini MK (2006). CD8 T cell hyporesponsiveness in chronic HBV infection: Role of CD3-zeta downregulation.
    • Turner J, Bansi L, Gilson R, Sabin C (2006). Hepatitis C virus (HCV) co-infection in HIV-infected patients in the UK Collaborative HIV Cohort (CHIC) Study..
    • Hopkins S, Barry O, Turner J, Johnson MA, Mulcahy F, Gilson R, Farrell G, Bhagani S, Bergin C (2006). Nadir CD4 does not predict response to pegylated-interferon and ribavirin in HIV-HCV co-infected patients..
    • Benzie A, Bansi L, Sabin C, Walsh J, Phillips A, for the UKCHIC Study Group (2006). Viral rebound in patients on antiretroviral therapy with viral suppression: association with extent of previous virological failure and time with viral suppression.
    • Grover D, Prime KP, Prince MV, Ridgway G, Gilson RJ (2006). Rectal gonorrhoea in men - is microscopy still a useful tool?. International Journal of STD and AIDS, 17(4), 277 - 279. doi:10.1258/095646206776253363
    • Maw R, on behalf of the HPV Special Interest Group of BASHH (2006). Testing guidelines for individual sexually transmitted infections: Anogenital warts.. Sexually Transmitted Infections, 82(Supplement IV), iv40 - iv41.
    • Gilson R, Brook MG (2006). Testing guidelines for individual sexually transmitted infections: Hepatitis A, B, and C.. Sexually Transmitted Infections, 82(Supplement IV), iv35 - iv39.
    • Garcia A, Nebbia G, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti A-M (2006). Occult hepatitis B in HIV-infected persons: prevalence, predictive factors and kinetics in response to HAART..

    2005

    • Geretti AM, Sabin C, Dunn D, Nebbia G, on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort CHIC Study Group (2005). Mutations at reverse transcriptase (RT) codons G196, Q207, H208, R211 and L214 are associated with drug experience and specific RT mutation patterns..
    • Grover D, Allen L, Edwards SG, Green H, Copas A, Forsyth S, Pillay D, on behalf of the UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study UKCHIC (2005). Predictors of death, and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK..
    • Gilson R (2005). Sorting out genital warts. Trends in Urology Gynaecology and Sexual Health, 10(4), 26 - 30.
    • Danta M, Turner JM, Johnstone R, Lascar RM, Johnson MA, Dusheiko GM, Williams IG, Gilson RJC, Bhagani S (2005). Use of pegylated interferon-alpha (peg-IFN) with or without ribavirin in the treatment of acute HCV in HIV-positive individuals..
    • Grover D, Allen L, Pillay D, Green H, Copas A, Forsyth S, Edwards SG, on behalf of the UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study UKCHIC (2005). Virological and clinical outcomes in patients with multi (three)-class drug resistant (MDR) HIV in the UK..
    • Easterbrook P, Bansi L, Sabin CA, Welz T, on behalf of the UK Collaborative HIV Cohort CHIC Study (2005). What is the clinical significance of sustained low-level viraemia (SLLV) in patients on HAART?.
    • Dunn C, Brunetto M, Flinchman D, Lampertico P, Meier U, Borrow P, Gilson RJ, Bertoletti A, Maini MK (2005). Immunomodulatory effects of the large fluctuations in IFN-γ and IL-8 accompanying hepatic flares in anti-HBe chronic HBV patients..
    • Danta M, Turner JM, Johnstone R, Lascar M, Johnson MA, Dusheiko GM, Williams IG, Gilson RJC, Bhagani S (2005). Early ribavirin improves sustained virological responses in acute HCV infection in HIV-positive individuals..
    • Turner J, Hopkins S, Mahungu T, Johnstone R, Lascar RM, Bhagani S, Dusheiko G, Johnson MA, Williams I, Gilson RJC (2005). Does nadir CD4 count in HIV-HCV co-infected patients predict HCV treatment response to pegylated interferon (p-IFN) and ribavirin (RBV)?.
    • Rider A, Gilson RJC, Sabin CA, on behalf of the UKCHIC Steering Committee (2005). Discordant CD4 and viral load responses in patients starting HAART in the UK Collaborative HIV Cohort (CHIC) Study..
    • Reeves I, Fisher M, Hill T, Sabin C, on behalf of the UK Collaborative HIV Cohort CHIC Steering Committee (2005). CD4 counts and the risk of lymphoma in individuals with HIV in the UK..
    • Stöhr W, Dunn D, Porter K, Sabin C, on behalf of the UK CHIC Study Steering Committee (2005). CD4 cell count and starting ART: trends in six UK centres 1997 – 2002..
    • Brook MG, Gilson R, Wilkins E, and the BHIVA Hepatitis Co-infection Guideline Committee on behalf of the British HIV Association (2005). BHIVA guidelines on HIV and chronic hepatitis: co-infection with HIV and hepatitis B virus infection.. HIV Medicine, 6(suppl 2), 84 - 95.
    • Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN (2005). Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ (Clinical Research Ed.), 330(7493), 695 - 699. doi:10.1136/bmj.38369.669850.8F
    • Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D (2005). Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.. AIDS, 19(5), 487 - 494.
    • Gilson RJC, Ross J, Maw R, Rowen D, Sonnex C, Lacey CJN (2005). A multi-centre, randomised, double-blind, placebo-controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream (Wartec®/Warticon®) as treatment for external anogenital warts..
    • Lascar RM, Lopes AR, Gilson RJC, Dunn C, Johnstone R, Copas A, Reignat S, Webster G, Bertoletti A, Maini MK (2005). Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. The Journal of Infectious Diseases, 191(7), 1169 - 1179. doi:10.1086/428502
    • Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Matthias R, Scullard G, Johnson MA, Sabin CA (2005). The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. The Journal of Infectious Diseases, 192(8), 1387 - 1397. doi:10.1086/466534

    2004

    • Gilson RJC (2004). Viral hepatitis.. In Adler MA, Cowan F, French P, Mitchell H, Richens J (Ed.), ABC of Sexually Transmitted Infections (pp. 62 - 67). : BMJ Publishing Group Ltd.
    • Sabin C, Babiker A, Dunn D, Easterbrook P, Fisher M, Gilson R, Johnson M, Mortimer J, Peters B, Phillips A, Porter K, Scullard G, Gazzard B, Matthias R, Hill T (2004). The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine, 5(2), 115 - 124.
    • Pillay D, Green H, Gazzard B, Pozniak A, Matthias R, Johnson M, Churchill D, Fisher M, Hill T, Geretti AM, Clarke J, Cane P, Loveday C, Scullard G, Easterbrook P, Porter K, Williams I, Gilson R, Sabin C, Phillips A, Dunn D (2004). Estimating resistance in drug experienced patients in the UK.
    • Bhaskaran K, Pillay D, Walker AS, Fisher M, Hawkins D, Gilson R, McLean K, Porter K (2004). Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS, 18(10), 1471 - 1473.
    • Das A, Lopes AR, Dunn C, Gotto J, Gilson RJ, Bertoletti A, Maini MK (2004). Downregulation of CD3 zeta chain: A mechanism for T-cell dysfunction in patients with chronic HBV infection..
    • Turner JM, Johnstone R, Lascar RM, Williams I, Gilson RJC (2004). Outcome of acute hepatitis C in HIV positive men..
    • Haddow LJ, Bunn A, Copas AJ, Gilson R, Prince M, Ridgway G, Sadiq ST (2004). Polymorph count for predicting non-gonococcal urethral infection: a model using Chlamydia trachomatis diagnosed by ligase chain reaction.. Sexually Transmitted Infections, 80(3), 198 - 200. doi:10.1136/sti.2003.006924
    • Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D (2004). Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice.

    2003

    • Brook MG, Gilson R, Wilkins EL, on behalf of the British HIV Association (2003). BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus.. HIV Medicine, 4(Sup1), 42 - 51. doi:10.1046/j.1468-1293.4.s1.1.x
    • Lascar RM, Smith A, Smith S, Macfarlane E, Gilson RJC (2003). Outcome of acute hepatitis C in HIV-positive homosexual men..
    • Prime KP, Grover D, Prince MV, Ridgway G, Gilson RJC (2003). Rectal gonorrhoea in men – is microscopy still a useful tool?.
    • Corden S, Ballard AL, Ijaz S, Barbara JA, Gilbert N, Gilson RJ, Boxall EH, Tedder RS (2003). HBV DNA levels and transmission of hepatitis B by health care workers. Journal of Clinical Virology, 27(1), 52 - 58. doi:10.1016/S1386-6532(02)00127-0
    • Creighton S, Prime K, Moore E, Bent P, Kelly M, Miller R, Gilson R (2003). Attendance at a young women’s clinic; more than contraception and STIs..
    • Lascar RM, Gilson RJC, Lopes AR, Bertoletti A, Maini MK (2003). Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. The Journal of Infectious Diseases, 188(12), 1815 - 1819. doi:10.1086/379896

    2002

    • Tedder RS, Ijaz S, Gilbert N, Barbara JA, Corden SA, Gilson RJ, Boxall EH (2002). Evidence for a dynamic host-parasite relationship in e-negative hepatitis B carriers. Journal of Medical Virology, 68(4), 505 - 512. doi:10.1002/jmv.10241
    • Cooksley H, Chokshi S, Wedemeyer H, Andreone P, Gilson RJC, Warnes T, Paganin S, Zoulim F, Jain A, James C, Gibbs C, Fry J, Brosgart C, Naoumov N (2002). Hepatitis B virus specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: a multicentre, controlled study..
    • McSorley J, Gilson R (2002). Sexual disease in male patients.. Practitioner, 246, 802 - 810.
    • Cooksley H, Chokshi S, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Jain A, James C, Gibbs C, Fry J, Brosgart C, Naoumov N (2002). Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: A multicentre, controlled study.
    • Lascar RM, Johnstone R, Bertoletti A, Gilson RJC, Maini MK (2002). Impact of antiretroviral therapy on hepatitis B virus (HBV)-specific immune responses on HIV/HBV co-infected patients..

    2001

    • Heathcote EJ, Jeffers L, Perrillo R, Wright T, Sherman M, Gilson R, Shakil AO, Namini H, James C, Ho V, Xiong S, Fry J, Brosgart C (2001). Viral suppression and HBeAg-seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B infection..
    • Heathcote EJ, Jeffers L, Perrillo R, Wright T, Sherman M, Gilson R, Shakil AO, Namini H, James C, Ho V, Fry J, Brosgart CL (2001). Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients..
    • Gilson RJC, Mindel A (2001). Recent advances: Sexually transmitted infections. BMJ (Clinical Research Ed.), 322(7295), 1160 - 1164. doi:10.1136/bmj.322.7295.1160
    • Bell A, Ncube F, Hansell A, Davison KL, Young Y, Gilson RJC, Macdonald N, Heathcock R, Warburton F, Maguire H (2001). An outbreak of hepatitis A among young men associated with having sex in public venues.. Communicable Diseases Public Health, 4(3), 163 - 170.

    2000

    • Maini MK, Boni C, Lee K, Larrubia JR, Reignat S, Ogg GS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov N, Ferrari C, Bertoletti A (2000). The role of virus-specific CD8+cells in liver damage and viral control during persistent hepatitis B virus infection.
    • Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov NV, Ferrari C, Bertoletti A (2000). The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. Journal of Experimental Medicine, 191(8), 1269 - 1280. doi:10.1084/jem.191.8.1269
    • Smith AM, Williams IG, Gilson RJC (2000). Sexually acquired acute hepatitis C in homosexual men with HIV infection..

    1999

    • UK Register of HIV Seroconverters Steering Committee (1999). How soon after HIV seroconversion is antiretroviral therapy initiated?. AIDS, 13(10), 1241 - 1247.
    • Gilson RJC, Weller IVD (1999). Hepatitis and human immunodeficiency virus infection in homosexual men and injecting drug users. In McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J (Ed.), Oxford Textbook of Clinical Hepatology (pp. 965 - 973). : .
    • Gilson RJC, Shupack JL, Friedman-Kien AE, Conant MA, Weber JN, Nayagam AT, Swann RV, Pietig DC, Smith MH, Owens ML, and the Imiquimod Study Group (1999). A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients..
    • Gilson RJC, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IVD (1999). A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis, 6(5), 387 - 395. doi:10.1046/j.1365-2893.1999.00182.x
    • Rooney G, Higgins J, Cowan FM, Gilson RJC (1999). Systematic review of sexual transmission of hepatitis C virus infection..

    1998

    • Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Canthers R, Rugizi V, Di Biseeglie A, Baian V, Murray A, Rooney G, Jaffe HS, for the Adefovir Dipivoxil HBV Study Team (1998). Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies..
    • Gilson RJC, Murray-Lyon I, Nelson MR, Rice SJ, Tedder RS, Murray A, Jaffe HS, Weller IVD (1998). Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection.
    • Gilson RJC, Murray-Lyon I, Nelson MR, Rice SJ, Tedder RS, Murray A, Jaffe HS, Weller IVD (1998). Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection..
    • Rooney G, Gilson RJC (1998). Sexual transmission of hepatitis C virus infection. Sexually Transmitted Infections, 74(6), 399 - 404. doi:10.1136/sti.74.6.399
    • UK Register of HIV Seroconverters Steering Committee (1998). The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS, 12(6), 659 - 667.
    • Rooney G, Johnstone R, Bean P, Williams D, Gilson RJC, Williams IG (1998). Use of protease inhibitors in HIV infected patients co-infected with chronic hepatitis B: a case series..
    • Weller IVD, Gilson RJC (1998). Viral Hepatitis. In Adler MW (Ed.), ABC of Sexually Transmitted Diseases (pp. 28 - 32). : BMJ Books.
    • Chokshi S, Papakonstantinou A, Gilson RJC, Johnstone R, Lopes AR, Weller IVD, Williams R, Naoumov NV (1998). Hepatitis flares in patients with adefovir dipivoxil correlate with activation of hepatitis B core-specific T cell reactivity..
    • Gilson RJC, de Ruiter A, Waite J, Ross E, Loveday C, Howell DR, Tedder RS, Weller IVD (1998). Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage. Sexually Transmitted Infections, 74(2), 110 - 115. doi:10.1136/sti.74.2.110

    1997

    • Fakoya A, Matear PM, Filley E, Rook GAW, Stanford J, Gilson RJC, Beecham N, Weller IVD, Vyakarnam A (1997). HIV infection alters the production of both type 1 and type 2 cytokines but does not induce a polarised type 1 or type 2 state. AIDS, 11(12), 1445 - 1452. doi:10.1097/00002030-199712000-00008
    • Heptonstall J, Barnes J, Burton E, Chattopadyhay B, McMillan L, Sullivan K, Tarling R, Viniker D, Boxall E, Cartmill I, Chatterjea M, Neill R, Collins M, Gill N, Ngui SL, Parker C, Ryan M, Teo CG, Coyle P, Craske J, Paver K, Gilson R, Hawkins A, Tedder R, Watts P, Zuckerman M, Morris D, Nazareth B (1997). Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. NEW ENGL J MED, 336(3), 178 - 184.
    • Gilson RJC (1997). Review of last month's publications. Keeping abreast of adverse events. AIDS Targeted Information, 11, R137 - R138.
    • Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, McNally T, Kelly GE, Tedder RS, Weller IV (1997). Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS, 11(5), 597 - 606. doi:10.1097/00002030-199705000-00007
    • Rooney G, Direkze N, Copas A, Gilson RJC (1997). Can we improve compliance with hepatitis B vaccination in genitourinary medicine clinics?.

    1996

    • Tang KY, Chan T, Fenton KA, Gilson RJC (1996). Hepatitis B in the Chinese community in Britain. BRIT MED J, 312(7029), 507 - 507.
    • Gilson RJC, Chopra K, Murray-Lyon I, Newell M, Nelson M, Tedder RS, Toole J, Jaffe HS, Hellmann N, Weller IVD (1996). A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM-PMEA) in patients with chronic hepatitis B infection..
    • Gilson RJC, Chopra K, Murray-Lyon I, Newell M, Nelson M, Tedder RS, Toole J, Jaffe HS, Hellmann N, Weller IVD (1996). A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM-PMEA) in patients with chronic hepatitis B infection..
    • Gilson RJC (1996). Early HIV infection - Clinical features and management.. In Mindel A, Miller R (Ed.), AIDS: A pocket book of diagnosis and management (pp. 42 - 54). : Arnold.
    • Hawkins AE, Zuckerman MA, Briggs M, Gilson RJC, Goldstone AH, Brink NS, Tedder RS (1996). Hepatitis B nucleotide sequence analysis: linking an outbreak of acute hepatitis B to contamination of a cryopreservation tank.. Journal of Virological Methods, 60, 81 - 88.
    • Gilson RJC (1996). Hepatitis B and admission to medical school - More flexibility should allow infectious applicants to follow non-invasive medical careers. BRIT MED J, 313(7061), 830 - 831.
    • Hawkins AE, Gilson RJC, Gilbert N, Wreghitt TG, Gray JJ, Ahlers-de Boer I, Tedder RS, Alexander GJM (1996). Hepatitis B virus surface mutations associated with infection after liver transplantation. Journal of Hepatology, 24(1), 8 - 14. doi:10.1016/S0168-8278(96)80179-6
    • Hawkins AE, Zuckerman MA, Goldstone AH, Gilson RJC, Heptonstall J, Tedder RS (1996). Identification of a common source outbreak of hepatitis B infection in a bone marrow transplant facility by nucleotide sequence analysis..
    • Maini NK, Gilson RJ, Chavda N, Gill S, Fakoya A, Ross EJ, Phillips AN, Weller IVD (1996). Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourinary Medicine, 72(1), 27 - 31. doi:10.1136/sti.72.1.27
    • UK Register of HIV Seroconverters Steering Committee (1996). The UK register of HIV seroconverters: methods and analytical issues. Epidemiology and Infection, 117(2), 305 - 312. doi:10.1017/S0950268800001485
    • Zuckerman M, Hawkins A, Heptonstall J, Watts P, Gilson R, Tedder R (1996). Hepatitis B transmission involving anti-HBe carrier surgeons - HBV DNA and nucleotide sequence analysis..

    1995

    • Zuckerman MA, Hawkins AE, Briggs M, Waite J, Balfe P, Gilson RJC, Tedder RS (1995). The investigation of hepatitis B transmission in an health care setting - application of direct sequence analysis.. The Journal of Infectious Diseases, 172, 1080 - 1083.
    • Fakoya A, Matear PM, Filley E, Rook GAW, Stanford J, Gilson RJC, Maini M, Weller IVD, Vyakarnam A (1995). TH1/TH2 or TH0-questionable cytokine patterns in healthy HIV-infected individuals. (Abstract D4-219).
    • FAKOYA A, MATEAR PM, FILLEY E, ROOK GAW, STANFORD J, GILSON RJC, MAINI M, WELLER IVD, VYAKARNAM A (1995). TH1/TH2 OR TH0-QUESTIONABLE CYTOKINE PATTERNS IN HEALTHY HIV-INFECTED INDIVIDUALS.
    • Weller IVD, Gilson RJC (1995). Viral hepatitis. In Adler M (Ed.), ABC of Sexually Transmitted Diseases (pp. 28 - 31). : John Wiley & Sons.

    1994

    • Hawkins AE, Gilson RJC, Beath SV, Boxall EH, Kelly DA, Tedder RS, Weller IVD (1994). Novel application of a point mutation assay: evidence for transmission of hepatitis B viruses with precore mutations and their detection in infants with fulminant hepatitis B.. Journal of Medical Virology, 44(1), 13 - 21. doi:10.1002/jmv.1890440105
    • Gilson RJC, Hawkins AE, Tedder RS, Weller IVD (1994). In-vitro suppression of hepatitis B virus DNA polymerase activity by 9-(2-phosphonylmethoxyethyl) adenine..
    • Hawkins AE, Gilson RJC, Bickerton EA, Tedder RS, Weller IVD (1994). Conservation of precore and core sequences of hepatitis B virus in chronic viral carriers.. Journal of Medical Virology, 43(1), 5 - 12. doi:10.1002/jmv.1890430103

    1993

    • Hawkins AE, Gilson RJC, Gilbert N, Boxall EH, Hatzakis A, Tedder RS, Weller IVD (1993). Clinical significance of hepatitis B virus mutants: application of a novel assay for point mutations..
    • Sweeney BJ, Manji H, Gilson RJC, Harrison MJG (1993). Optic neuritis and HIV-1 infection.. Journal of Neurology, Neurosurgery and Psychiatry, 56(6), 705 - 707. doi:10.1136/jnnp.56.6.705
    • Noble PR, Gilson RJC (1993). Hepatitis C: recent advances.. Maternal and Child Health, 18, 70 - 74.
    • Maini M, Manning P, Gilson RJC (1993). Impotence - all in the head?.
    • Maini M, Gilson RJC, Adolphus N, Fakoya A, Ross E, Phillips AN (1993). Normal range and sources of variability of CD4 counts in HIV-seronegative women and heterosexual men..

    1992

    • Gilson R (1992). Hepatitis B vaccination: who, when, and why?. Prescriber, 3, 94 - 100.
    • French PD, Gilson RJC (1992). Conference Report: The International Society for STD Research Ninth International Meeting, Banff, Canada, October 1991. Genitourinary Medicine, 68(3), 189 - 191.
    • GILSON RJC, SEMPLE M, GILL SK, LOVEDAY C, TEDDER RS, WELLER IVD (1992). LACK OF SUPPRESSION BY RIBAVIRIN OF HIV VIREMIA. LANCET, 339(8809), 1605 - 1606.
    • GILL SK, LOVEDAY C, GILSON RJC (1992). TRANSMISSION OF HIV-1 INFECTION BY OROANAL INTERCOURSE. GENITOURIN MED, 68(4), 254 - 257.
    • HAWKINS A, GILSON R, TEDDER RS, WREGHITT TG, ALEXANDER GJM (1992). HEPATITIS-B VIRUS ESCAPE MUTANT FOLLOWING LIVER-TRANSPLANTATION.
    • Gilson RJC, Semple M, Gill SK, Loveday C, Tedder RS, Weller IVD (1992). Lack of suppression by ribavirin of HIV viraemia. (Letter). The Lancet, 339, 1605 - 1606.
    • Gill SK, Loveday C, Gilson RJC (1992). Transmission of HIV-1 by oroanal intercourse. Genitourinary Medicine, 68(4), 254 - 257.
    • Gilson RJC (1992). Sexually transmitted hepatitis: a review.. Genitourinary Medicine, 68(2), 123 - 129.

    1991

    • Bhatti N, Gilson RJC, Beecham M, Williams P, Matthews MP, Tedder RS, Weller IVD (1991). Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ (Clinical Research Ed.), 303(6794), 97 - 101. doi:10.1136/bmj.303.6794.97
    • Tedder RS, Gilson RJ, Briggs M, Loveday C, Cameron CH, Garson JA, Kelly GE, Weller IV (1991). Hepatitis C virus: evidence for sexual transmission. BMJ (Clinical Research Ed.), 302(6788), 1299 - 1302. doi:10.1136/bmj.302.6788.1299
    • Kani J, Nandwani R, Gilson RJ, Johnson AM, Maguire HC, Tedder RS (1991). Hepatitis A virus infection among homosexual men (Letter). BMJ (Clinical Research Ed.), 302(6789), 1399 - .
    • Gilson RJC, Weller IVD (1991). Hepatitis and human immunodeficiency virus infection in homosexual men and injecting drug users. In McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J (Ed.), Oxford Textbook of Clinical Hepatology (pp. 1311 - 1318). : Oxford University Press.
    • Miller RF, Gilson R, Hage C, Scaravilli F, Michaels L (1991). HIV-associated dilated cardiomyopathy.. Genitourinary Medicine, 67, 453 - 459.
    • Gill SK, Gilson RJC, Rickards D (1991). Multiple prostatic abscesses presenting with urethral discharge. Genitourinary Medicine, 67(5), 411 - 412. doi:10.1136/sti.67.5.411
    • Gilson RJC, Hawkins AE, Kelly G, Gill S, Weller IVD (1991). No effect of zidovudine on hepatitis B virus replication in homosexual men with symptomatic HIV-1 infection. AIDS, 5(2), 217 - 220.

    1990

    • Gilson RJC (1990). Early HIV infection - Clinical features and management. In Mindel A (Ed.), AIDS: A pocket book of diagnosis and management. (pp. 33 - 46). : Edward Arnold.
    • Gilson RJC, De Ruiter A, Waite J, Loveday C, Kelly G, Weller IVD (1990). Seroprevalence of hepatitis B virus infection in patients attending a genitourinary medicine clinic.
    • Gilson RJC, Tedder RS, Garson J, Briggs M, Loveday C, Weller IVD (1990). Hepatitis C virus infection: another sexually transmitted disease?.
    • Hawkins A, Gilson RJC, Tedder RS, Weller IVD (1990). Interactions between hepatitis B virus (HBV) and HIV in homosexual men..

    1989

    • Gilson RJC, Tedder RS, Weller IVD (1989). Hepatitis B: reactivation or reinfection associated with HIV-1 infection. The Lancet, 2(8675), 1330 - .

    1988

    • Gilson RJC, Timmins DJ (1988). Genital chlamydial infection.. Current Opinion in Infectious Disease, 1, 16 - 20.
    • Waite J, Gilson RJC, Weller IVD, Lacey CJN, Hambling MH, Hawkins A, Briggs M, Tedder RS (1988). Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS, 2(6), 443 - 448. doi:10.1097/00002030-198812000-00006
    • Gilson RJC, Weller IVD, Hawkins A, Waite J, Carne C, Robinson AJ, Kelly G, Briggs M, Tedder RS (1988). Interactions between hepatitis B virus (HBV) and HIV in homosexual men..
    • GILSON RJC, TIMMINS DJ (1988). CHLAMYDIAL INFECTION. CURR OPIN INFECT DIS, 1(1), 16 - 20.
    • Gilson R (1988). Clinical aspects of AIDS. Medicine International, 57, 2344 - 2352.

    1987

    • Gilson RJC, Weller IVD (1987). Human immunodeficiency virus (HIV) infection for the general physician.. Postgraduate Medical Journal, 63, 427 - 433.

    1986

    • Bingham JS, Gilson RJC (1986). AIDS - how much have we learnt. Practitioner, 230, 851 - 855.

    1985

    • Struthers GR, Andrews DJ, Gilson RJC, Reynold GA, Lowbeer T (1985). Intestinal permeability (Letter). The Lancet, 1, 587 - 588.

    1981

    • Miller GJ, Gilson RJC (1981). Similarity in males and females of HDL-2 and HDL-3 cholesterol concentration in a Caribbean rural community.. Atherosclerosis, 40, 75 - 80.

    1978

    • Miller GJ, Serjeant GR, Saunders MJ, Richardson C, Gilson RJC (1978). Interpretation of lung function tests in the sickle-cell haemoglobinopathies.. Thorax, 33, 85 - 88.

    1977

    • Miller GJ, Saunders MJ, Gilson RJC, Ashcroft MT (1977). Lung function of healthy boys and girls in Jamaica in relation to ethnic composition, test exercise performance and habitual physical activity.. Thorax, 32, 486 - 496.

    1976

    • Miller GJ, Saunders MJ, Gilson RJC, Ashcroft MT (1976). Superior lung function of Jamaican children in a hill-farming community as compared with their urban compatriots.. Thorax, 31, 481 - 482.